Explore This Research Award in CaptureIQ
Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.
Award details
- Awarding agency
- National Science Foundation
- Branch
- Not reported
- Recipient company
- SENOGUARD INC
- Proposal award date
- 2024-12-05
- Contract end date
- 2026-11-30
- UEI
- ML89LRJMK3D7
- Solicitation number
- NSF 23-516
- Topic code
- MD
Research abstract
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase II project is a novel minimally invasive thermal therapy for improving post surgical lumpectomy outcomes. In the US, 300,000 new breast cancer cancer diagnoses occur each year with nearly half, or 150,000, undergoing surgical excision of the tumor. These patients are also required to undergo subsequent radiation therapy to decrease the risks of recurrence. The follow on treatments require multiple follow up visits to hospitals or clinics with specialized equipment and personnel, disproportionately affecting social and economically disadvantaged patients in underserved regions. This initiative aims to provide an adjunctive therapy to be performed by the breast cancer surgeon immediately following a lumpectomy, in order to significantly reduce or eliminate remaining cancerous cells in the surrounding tissue or fluid medium. The proposed benefits include reducing the rates and severity of side effects of radiation therapy, as well as reducing multiple inclinic follow up visits. The system represents a novel treatment paradigm for breast cancer - the most commonly diagnosed form of cancer in the female population affecting one in eight women, and fifth leading cause of cancer death worldwide with 2.3 million new cases and 685,000 deaths per year. The potential commercial impact is a new type of cryogenic probe and treatment paradigm for the $7.5B annual breast cancer lumpectompy and invasive treatment market.
This Small Business Innovation Research (SBIR) Phase II project aims to complete engineering and validation activities for a novel minimally invasive cryoablation probe, coupled with an external cryoagent controller, for performing post lumpectomy augmentative therapy. The cryoablation probe will be optimized for procedural and development considerations based on a gel model in order to ensure proper contact with the tumor cavity walls to induce necrosis or apopt
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
Research funding history
2 SBIR/STTR records share this UEI (2023–2025). Reported award amounts total $1,255,276. Reported amounts are not federal obligations.
Phases: Phase II, Phase I
Agencies: National Science Foundation
Agency intelligence
National Science Foundation
Back to SBIR/STTR Research Awards